Analyst Research

Report Title Price
Provider: BuySellSignals Research
$5.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ranbaxy Laboratories Ltd Receives Approval From CDSCO To Market Synriam


Monday, 21 Oct 2013 01:06am EDT 

Ranbaxy Laboratories Ltd announced that it has received Central Drugs Standard Control Organisation (CDSCO) approval to market Synriam (arterolane maleate and piperaquine phosphate tablet 150+750 mg) in India for the treatment of uncomplicated malaria in adults caused by plasmodium vivax parasite. Phase III clinical trials for the drug conducted in India, successfully demostrated the efficacy and tolerability for Synriam as comparable to chloroquine. The Company also received permission to conduct Phase III clinical trials for the pediatric formulation in the pediatric patients of uncomplicated plasmodium falciparum malaria. 

Company Quote